AGL Valuation - Is Agilon Health Inc Over or Undervalued?

Comprehensive analysis of Agilon Health Inc valuation metrics including P/E, P/B, P/S, and EV/EBITDA ratios

Updated March 18, 2026-6 min read-View Full Analysis

Current Stock Price

$0.61

Market Cap

$0.25B

Valuation Date

Mar 18, 2026

Valuation Verdict

Potentially Undervalued

Based on valuation multiples, AGL appears attractively priced. 1 key metrics suggest potential value opportunity.

Key Valuation Metrics

These four fundamental valuation ratios help determine if AGL is trading at a fair price relative to its earnings, assets, revenue, and cash flow generation.

P/E Ratio (Price-to-Earnings)

N/A

Not profitable or data unavailable

P/B Ratio (Price-to-Book)

Good

1.95x

Moderate premium

Stock trades at 1.95x its book value per share

P/S Ratio (Price-to-Sales)

Good

0.04x

Low relative to sales

Market values each $1 of revenue at $0.04

EV/EBITDA

N/A

EBITDA data unavailable

How to Interpret These Metrics

P/E Ratio: Lower P/E often indicates better value, but compare against industry peers. High-growth companies typically have higher P/E ratios. Market average is 15-20x.

P/B Ratio: Values below 1.0 suggest the stock trades below its net asset value, which could indicate undervaluation or fundamental problems. Technology companies often trade at higher P/B ratios.

P/S Ratio: Useful for unprofitable companies or comparing revenue efficiency. Lower is generally better, but high-margin businesses can justify higher P/S ratios.

EV/EBITDA: Accounts for debt and excludes non-cash expenses, making it ideal for comparing companies with different capital structures. Values under 10x often indicate good value.

How AGL Compares to Peers

What This Means for Investors

Potential Value Opportunity

Agilon Health Inc (AGL) currently trades at valuation multiples that appear attractive relative to historical averages and peer comparisons. This could represent a buying opportunity for long-term investors who believe in the company's fundamentals. However, always investigate why the market is pricing the stock this way - there may be legitimate concerns about future growth or profitability.

Bullish Considerations

Reasonable price relative to book value
Attractive price-to-sales multiple
Multiple metrics suggest undervaluation

Bearish Considerations

Complete Your Analysis

Valuation is just one piece of the puzzle. Get the complete picture of AGL with our comprehensive analysis tools.

Full Stock Analysis

Complete financials, charts, and metrics

Should I Buy AGL?

AI-powered investment recommendation

Price Forecast

Future price targets and predictions

Analyst Ratings

Wall Street consensus and targets

Deep Valuation Analysis

DCF model and intrinsic value

Frequently Asked Questions

What is AGL's P/E ratio and what does it mean?

AGL has a P/E (Price-to-Earnings) ratio of N/A. This means investors are paying $N/A for every $1 of annual earnings. A lower P/E generally suggests better value, but it's important to compare against industry peers and growth prospects. The market average P/E is typically 15-20x.

Is AGL stock overvalued or undervalued?

Based on our analysis of key valuation metrics (P/E, P/B, P/S, EV/EBITDA), AGL appears potentially undervalued. Based on valuation multiples, AGL appears attractively priced. 1 key metrics suggest potential value opportunity. However, valuation is just one factor to consider alongside growth prospects, competitive position, and market conditions.

What is a good P/E ratio for AGL?

There's no single "good" P/E ratio as it varies by industry and growth stage. For Agilon Health Inc, compare the current P/E of N/A against: (1) Industry peers, (2) Historical average P/E for AGL, (3) Expected earnings growth rate. High-growth companies often justify higher P/E ratios, while mature companies typically trade at lower multiples.

How do I use valuation ratios to make investment decisions?

Valuation ratios are screening tools, not buy/sell signals. Use them to: (1) Compare AGL against competitors, (2) Identify potential over/undervaluation, (3) Understand what you're paying for earnings, assets, or sales. Combine valuation analysis with fundamental research, growth prospects, and technical analysis for comprehensive decision-making.

What is EV/EBITDA and why does it matter?

EV/EBITDA (Enterprise Value to EBITDA) is N/A for AGL. This ratio is useful because it accounts for debt and excludes non-cash expenses, making it better for comparing companies with different capital structures. Lower EV/EBITDA generally indicates better value. It's particularly useful for comparing companies in capital-intensive industries.

Disclaimer: This valuation analysis is for informational and educational purposes only and should not be considered investment advice. Valuation metrics are just one factor in investment decisions. Always conduct comprehensive research and consult with a qualified financial advisor before making investment decisions. Past performance and current valuations do not guarantee future results.